ADMA News and Press, ADMA Biologics Inc From 01/18/22

RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, ...

The FDA has updated the Emergency Use Authorization ("EUA") for the use of convalescent plasma as a COVID-19 treatment for patients with immunosuppressive disease or receiving immunosuppressive treatment. The FDA reiterated that the plasma product used must have high titers of anti-SARS-CoV-2...

Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...

The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...

ADMA Biologics (NASDAQ:ADMA) announces that the European Patent Office (EPO) has issued Patent No. 3375789, to the Company. Shares up 2.2% premarket at $1.41. This patent relates to the treatment and prevention of S. pneumonia infections, and in particular, to standardized hyperimmu...

Extends Existing U.S. Patent with Granted European Patent for Treatment and Prevention of S. Pneumococcal Infections with a Hyperimmune Globulin Reinforces Existing and Pending IP that Provides for ‘Spiking’ IG Pools with Monoclonal Antibodies to Create Novel Hyperim...

3 Penny Stocks to Watch in the Second Half of November As we dive further into the second half of November, penny stocks continue to be a popular choice among investors of all types. And, there are several reasons why that is the case. For one, penny stocks provide a high level of m...

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 17, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived bi...

RAMSEY, N.J. and BOCA RATON, Fla. and MYRTLE BEACH, S.C., Nov. 16, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing spec...

After the fifth consecutive revenue beat posted by the company with its Q3 2021 financials, Raymond James has upgraded ADMA Biologics (ADMA +14.3%) to Strong Buy from Outperform. The analysts led by Elliot Wilbur highlight a sequential improvement in its topline and a quarterly gros...